Welcome to our dedicated page for Core Laboratories SEC filings (Ticker: CLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Core Laboratories Inc. (CLB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Core Laboratories is listed on the New York Stock Exchange under the symbol CLB, and its filings include current reports on Form 8-K, annual and quarterly reports, and other documents that describe its financial condition, capital structure, and material events.
Recent 8-K filings referenced by the company include disclosures of quarterly financial results, dividend declarations, and a Ninth Amended and Restated Credit Agreement. That agreement increased the aggregate borrowing commitment, extended the maturity date of the credit facility, and outlined conditions related to outstanding senior notes, while noting that there were no material changes to other key terms such as collateral, pricing, and financial covenants.
Through this page, users can review Core Laboratories’ periodic reports to understand segment performance in Reservoir Description and Production Enhancement, management’s discussion of free cash flow and leverage, and details on capital allocation decisions such as share repurchases and dividends. Current reports on Form 8-K also document events like earnings releases, changes to credit arrangements, and other significant corporate actions.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly identify information about revenue trends, liquidity, debt facilities, and board-approved dividends. Users can also track updates related to credit agreements and other obligations described in filings, alongside real-time access to new submissions as they appear in the SEC’s EDGAR system.
Core Laboratories Inc. is asking shareholders to vote at its May 12, 2026 annual meeting on four items: re‑electing two Class I directors until 2029, ratifying KPMG LLP as auditor for 2026, approving on an advisory basis executive compensation, and handling any other proper business.
Shareholders of record at the close of business on March 18, 2026, when 46,048,268 common shares were outstanding, are entitled to one vote per share. The proxy describes a classified, majority‑independent board, detailed committee structure, and a pay program that is heavily performance‑based, with 100% of named executive officer long‑term incentives in performance share units tied primarily to return on invested capital and relative financial metrics.
The company highlights 2025 business results including operating margin of 10.7%, an estimated 9.8% return on invested capital relative to peers, and strong safety performance, and notes that 94.3% of votes cast in 2025 supported its executive pay program.
The Vanguard Group filed Amendment No. 4 to its Schedule 13G/A reporting 0 shares of Core Laboratories Inc. common stock. The filing states Vanguard's subsidiaries underwent an internal realignment on January 12, 2026, after which certain subsidiaries report beneficial ownership separately. The amendment shows Amount beneficially owned: 0 and Percent of class: 0%. The filing is signed by Ashley Grim as Head of Global Fund Administration on 03/26/2026.
Core Laboratories Inc. updated its outlook for first quarter 2026, warning that revenue and earnings will fall below guidance issued on February 4, 2026 due to the escalating Middle East conflict. The company now expects revenue between $119,000,000 and $123,000,000, with operating income ex-items of $5,700,000 to $7,100,000. Earnings per share ex-items are projected at $0.05 to $0.07. Client-driven project delays, travel constraints, supply-chain disruptions and damage to regional oil infrastructure are pressuring activity, especially in Reservoir Description, while Production Enhancement is less affected but facing shipment delays. Core plans to discuss results on an April 30, 2026 earnings call following an April 29, 2026 release.
Core Laboratories Inc. provides specialized reservoir description and production enhancement services to oil and gas companies worldwide. The company operates in more than 50 countries with about 3,300 employees, and reported consolidated revenue of $526,520,000 for the year ended December 31, 2025, primarily from services rather than products.
Two main segments drive results: Reservoir Description, focused on rock and fluid analysis and digital reservoir characterization, and Production Enhancement, which supplies perforating systems and diagnostics to optimize well completions and enhanced recovery. Core Lab is increasingly involved in carbon capture and storage and other energy transition projects, while remaining heavily exposed to oil and gas spending cycles.
The report highlights extensive risk factors, including industry cyclicality, geopolitical instability in regions such as the Middle East and Russia/Ukraine, evolving sanctions regimes, climate and environmental regulation, cybersecurity threats, supply chain concentration, and challenges in attracting technical talent. A significant portion of revenue is generated outside the United States, adding currency and regulatory risk alongside growth opportunities.
Core Laboratories Inc. is filing an amended current report to correct income tax accounting in its previously released 2025 results. Estimated income tax expense for the quarter and year ended December 31, 2025 increased by $4.2 million, reducing net income by the same amount and lowering diluted earnings per share by $0.09 per share. The change stems mainly from updated analyses of deferred tax assets and liabilities and the tax treatment of insurance proceeds from a fire at the company’s Aberdeen, U.K. facility. Core also corrected immaterial prior-period items, including a $5.6 million write-off of older income tax receivables and a $4.7 million misclassification between income tax receivable and deferred tax liabilities. The company states these tax adjustments do not affect consolidated revenue, operating income, income before tax, or cash from operations previously reported in its earnings release.
Core Laboratories Inc. changed its bylaws to make it easier for shareholders to approve major corporate actions. On February 27, 2026, the board adopted First Amended and Restated Bylaws that lower the voting threshold in Section 2.11 for certain shareholder approvals, including merger and change in control transactions, from a 66-2/3% supermajority vote to a simple majority of 50% plus one vote. This means fewer shares are now required to approve these significant transactions. The full text of the amended bylaws is provided as an exhibit to the filing.
Core Laboratories Inc. filed a Form 12b-25 notifying the SEC that its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 will be late. The company says it needs additional time to complete international income tax accounting analyses and management’s evaluation of internal controls.
The filing warns there could be a material, non-cash impact to income tax related balances and that management may conclude there was a significant deficiency or material weakness in internal control over financial reporting as of December 31, 2025. The company states the delay is not due to any disagreement with its independent registered public accounting firm. The notice was signed by Christopher S. Hill on March 3, 2026.
Core Laboratories Inc. reported that investment adviser Disciplined Growth Investors, Inc. filed an amended Schedule 13G showing a significant ownership stake. As of 12/31/2025, the adviser beneficially owned 5,166,914 common shares of Core Laboratories, representing 11.1% of the outstanding class.
The firm had sole power to vote 4,668,306 of these shares and sole power to dispose of all 5,166,914 shares, with no shared voting or dispositive power. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Core Laboratories.
Core Laboratories Inc. granted SVP, General Counsel and Secretary Mark Damian Tattoli 33,490 performance shares on February 12, 2026. These are derivative equity awards with no cash exercise price.
The award is tied to a three-year performance period from January 1, 2026 through December 31, 2028. Vesting, if any, occurs on December 31, 2028 and depends on the company’s Return on Invested Capital versus a Bloomberg Peer Group, ranging from 50% to 175% of the target award, with higher vesting for stronger relative performance and a reduction if total shareholder return over the period is negative.
Core Laboratories Inc. granted SVP Gwendolyn Gresham 33,490 performance shares on February 12, 2026 at an exercise price of $0. These shares relate to a three-year performance period from January 1, 2026 to December 31, 2028.
The award will vest, if at all, on December 31, 2028 based on the company’s Return on Invested Capital versus the Bloomberg Peer Group. Payout levels range from 50% to 175% of the target award, with straight-line interpolation and a reduction if total shareholder return is negative.